Clinical Trials
3 trialsNCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02779257 2022-03-04
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Phase 4 Withdrawn